[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA2292629C - Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione - Google Patents

Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Download PDF

Info

Publication number
CA2292629C
CA2292629C CA002292629A CA2292629A CA2292629C CA 2292629 C CA2292629 C CA 2292629C CA 002292629 A CA002292629 A CA 002292629A CA 2292629 A CA2292629 A CA 2292629A CA 2292629 C CA2292629 C CA 2292629C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
compound
composition
acceptable form
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002292629A
Other languages
English (en)
French (fr)
Other versions
CA2292629A1 (en
Inventor
Jaikrishna Patel
Hamish Ross
Robin Kevin John Price
Jeffrey Roger Granett
Paul Nigel Wray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of CA2292629A1 publication Critical patent/CA2292629A1/en
Application granted granted Critical
Publication of CA2292629C publication Critical patent/CA2292629C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002292629A 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Expired - Fee Related CA2292629C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GB9711683.4 1997-06-05
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition
GB9712851.6 1997-06-18
PCT/EP1998/003478 WO1998055122A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002333352A Division CA2333352A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
CA2292629A1 CA2292629A1 (en) 1998-12-10
CA2292629C true CA2292629C (en) 2004-01-06

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002292629A Expired - Fee Related CA2292629C (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
CA002333352A Abandoned CA2333352A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002333352A Abandoned CA2333352A1 (en) 1997-06-05 1998-06-02 Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione

Country Status (29)

Country Link
EP (1) EP0998284A1 (es)
JP (1) JP2001521553A (es)
KR (1) KR20010013410A (es)
CN (3) CN1526391A (es)
AP (1) AP1214A (es)
AR (2) AR015120A1 (es)
AU (1) AU8215098A (es)
BG (1) BG104048A (es)
BR (1) BR9810405A (es)
CA (2) CA2292629C (es)
CO (1) CO4940400A1 (es)
DZ (1) DZ2510A1 (es)
EA (1) EA002384B1 (es)
GB (1) GB9711683D0 (es)
HU (1) HUP0004070A3 (es)
ID (1) ID24264A (es)
IL (1) IL133074A0 (es)
MX (1) MXPA99011322A (es)
NO (2) NO995938L (es)
NZ (2) NZ523725A (es)
OA (1) OA11306A (es)
PE (1) PE78899A1 (es)
PL (1) PL337201A1 (es)
SK (1) SK164899A3 (es)
TR (2) TR199902963T2 (es)
TW (1) TW570797B (es)
UY (1) UY25032A1 (es)
WO (1) WO1998055122A1 (es)
ZA (2) ZA984826B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010040A1 (es) 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
ATE246191T1 (de) 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
KR19990036290A (ko) * 1995-08-10 1999-05-25 로즈 암스트롱 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법
AU7604596A (en) * 1995-11-17 1997-06-11 Warner-Lambert Company A method of treating myotonic dystrophy
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
EP0921798A1 (en) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Novel treatment of leptine resistance

Also Published As

Publication number Publication date
JP2001521553A (ja) 2001-11-06
NO995938D0 (no) 1999-12-03
EA199901116A1 (ru) 2000-06-26
PL337201A1 (en) 2000-08-14
AR015120A1 (es) 2001-04-18
BR9810405A (pt) 2000-08-29
AP1214A (en) 2003-10-08
WO1998055122A1 (en) 1998-12-10
CN1430959A (zh) 2003-07-23
CA2292629A1 (en) 1998-12-10
AU8215098A (en) 1998-12-21
IL133074A0 (en) 2001-03-19
ID24264A (id) 2000-07-13
PE78899A1 (es) 1999-10-22
KR20010013410A (ko) 2001-02-26
BG104048A (bg) 2000-07-31
NZ513922A (en) 2001-09-28
ZA984826B (en) 1999-08-03
NZ523725A (en) 2004-09-24
CO4940400A1 (es) 2000-07-24
UY25032A1 (es) 1998-11-26
HUP0004070A2 (hu) 2002-02-28
SK164899A3 (en) 2000-11-07
ZA9811572B (en) 1999-07-22
DZ2510A1 (fr) 2003-01-25
TR199902963T2 (xx) 2000-02-21
TR200002790T2 (tr) 2001-11-21
CN1259050A (zh) 2000-07-05
AP9901696A0 (en) 1999-12-31
EA002384B1 (ru) 2002-04-25
TW570797B (en) 2004-01-11
NO995938L (no) 2000-02-02
CN1526391A (zh) 2004-09-08
CN1112926C (zh) 2003-07-02
HUP0004070A3 (en) 2002-03-28
GB9711683D0 (en) 1997-08-06
AR008198A1 (es) 1999-12-29
MXPA99011322A (es) 2004-12-02
OA11306A (en) 2003-10-22
EP0998284A1 (en) 2000-05-10
CA2333352A1 (en) 1998-12-10
NO20040738L (no) 2000-02-02

Similar Documents

Publication Publication Date Title
EP0996444B1 (en) Treatment of diabetes with thiazolidinedione and metformin
CA2292629C (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
US20030187030A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
EP0999845B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU743269B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
AU9513401A (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
MXPA99012065A (es) Tratamiento de diabetes con rosiglitazona e insulina
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012098A (es) Tratamiento de diabetes con tiazolidinodiona e inhibidor de alfa-glucosidasa

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed